199 related articles for article (PubMed ID: 30709725)
1. Needle-free delivery of influenza vaccine using the Med-Jet® H4 is efficient and elicits the same humoral and cellular responses as standard IM injection: A randomized trial.
Shapiro JR; Hodgins B; Hendin HE; Patel A; Menassa K; Menassa C; Menassa M; Pereira JA; Ward BJ
Vaccine; 2019 Feb; 37(10):1332-1339. PubMed ID: 30709725
[TBL] [Abstract][Full Text] [Related]
2. Needle-free jet injection for administration of influenza vaccine: a randomised non-inferiority trial.
McAllister L; Anderson J; Werth K; Cho I; Copeland K; Le Cam Bouveret N; Plant D; Mendelman PM; Cobb DK
Lancet; 2014 Aug; 384(9944):674-81. PubMed ID: 24881803
[TBL] [Abstract][Full Text] [Related]
3. Nine μg intradermal influenza vaccine and 15 μg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults.
Nougarede N; Bisceglia H; Rozières A; Goujon C; Boudet F; Laurent P; Vanbervliet B; Rodet K; Hennino A; Nicolas JF
Hum Vaccin Immunother; 2014; 10(9):2713-20. PubMed ID: 25483667
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector.
Simon JK; Carter M; Pasetti MF; Sztein MB; Kotloff KL; Weniger BG; Campbell JD; Levine MM
Vaccine; 2011 Nov; 29(51):9544-50. PubMed ID: 21986218
[TBL] [Abstract][Full Text] [Related]
6. Dose sparing with intradermal injection of influenza vaccine.
Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
[TBL] [Abstract][Full Text] [Related]
7. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults.
Soonawala D; Verdijk P; Wijmenga-Monsuur AJ; Boog CJ; Koedam P; Visser LG; Rots NY
Vaccine; 2013 Aug; 31(36):3688-94. PubMed ID: 23770332
[TBL] [Abstract][Full Text] [Related]
8. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors.
Jackson LA; Austin G; Chen RT; Stout R; DeStefano F; Gorse GJ; Newman FK; Yu O; Weniger BG;
Vaccine; 2001 Sep; 19(32):4703-9. PubMed ID: 11535320
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
[TBL] [Abstract][Full Text] [Related]
11. Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses.
Jiang J; Ramos SJ; Bangalore P; Fisher P; Germar K; Lee BK; Williamson D; Kemme A; Schade E; McCoy J; Muthumani K; Weiner DB; Humeau LM; Broderick KE
Vaccine; 2019 Jun; 37(29):3832-3839. PubMed ID: 31174938
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™).
Fernando GJP; Hickling J; Jayashi Flores CM; Griffin P; Anderson CD; Skinner SR; Davies C; Witham K; Pryor M; Bodle J; Rockman S; Frazer IH; Forster AH
Vaccine; 2018 Jun; 36(26):3779-3788. PubMed ID: 29779922
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults.
Chi RC; Rock MT; Neuzil KM
Clin Infect Dis; 2010 May; 50(10):1331-8. PubMed ID: 20377407
[TBL] [Abstract][Full Text] [Related]
14. Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.
Garg S; Thongcharoen P; Praphasiri P; Chitwarakorn A; Sathirapanya P; Fernandez S; Rungrojcharoenkit K; Chonwattana W; Mock PA; Sukwicha W; Katz JM; Widdowson MA; Curlin ME; Gibbons RV; Holtz TH; Dawood FS; Olsen SJ
Clin Infect Dis; 2016 Feb; 62(3):383-391. PubMed ID: 26486702
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity.
Rosendahl Huber SK; Hendriks M; Jacobi RHJ; van de Kassteele J; Mandersloot-Oskam JC; van Boxtel RAJ; Wensing AMJ; Rots NY; Luytjes W; van Beek J
Front Immunol; 2018; 9():3103. PubMed ID: 30761157
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
Frey SE; Bernstein DI; Brady RC; Keitel WA; El Sahly H; Rouphael NG; Mulligan MJ; Atmar RL; Edupuganti S; Patel SM; Dickey M; Graham I; Anderson EL; Noah DL; Hill H; Wolff M; Belshe RB
Vaccine; 2015 Jan; 33(1):163-73. PubMed ID: 25444805
[TBL] [Abstract][Full Text] [Related]
18. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
